COVID-19 diagnostic test approval by FDA
Pro Research Analysisby 
Searched over 200M research papers
FDA Emergency Use Authorization (EUA) for COVID-19 Diagnostic Tests
The U.S. Food and Drug Administration (FDA) responded to the urgent need for COVID-19 testing by granting Emergency Use Authorization (EUA) to a wide range of diagnostic tests. This regulatory flexibility allowed for the rapid development, approval, and deployment of both molecular and serological tests to detect SARS-CoV-2, the virus responsible for COVID-19 Ching2020Ravi2020Habli2021+4 MORE.
Types of FDA-Approved COVID-19 Diagnostic Tests
Molecular Tests (RT-PCR and Nucleic Acid Tests)
Molecular tests, especially real-time reverse transcriptase polymerase chain reaction (RT-PCR), have been the gold standard for detecting active SARS-CoV-2 infection. These tests identify viral RNA in patient samples and are highly sensitive and specific. The FDA approved several RT-PCR-based kits, including the CDC 2019-nCoV RT-PCR Diagnostic Panel and rapid point-of-care molecular assays like Abbott’s ID NOW COVID-19 Test, which can deliver results in as little as five minutes Ravi2020Habli2021Vashist2020+2 MORE.
Serological (Antibody) Tests
Serological tests detect antibodies (IgG and IgM) produced in response to SARS-CoV-2 infection. These tests are useful for identifying individuals who have been exposed to the virus and for understanding community-level immunity. The FDA granted EUA to various serological assays, such as Cellex’s qSARS-CoV-2 IgG/IgM Rapid Test, which complement molecular tests but cannot confirm active infection Ching2020Ravi2020Habli2021+3 MORE.
Innovative and At-Home Diagnostic Tests
The FDA also authorized innovative diagnostic technologies, including the first CRISPR-based COVID-19 test developed by Sherlock Biosciences, marking a significant advancement in molecular diagnostics . Additionally, the FDA approved at-home and over-the-counter tests, including the first nonprescription test that can simultaneously detect COVID-19, influenza, and RSV, expanding access to rapid testing for respiratory illnesses Larkin2022Gottlieb2021.
Policy Changes and Impact on Diagnostic Testing
To address testing shortages and the urgent public health need, the FDA relaxed certain regulatory requirements, streamlined submission processes, and provided templates to reduce the burden on test developers. These changes enabled faster test development and approval, particularly for at-home diagnostics, and set a precedent for future public health emergencies Ching2020Oh2021Gottlieb2021.
Performance and Limitations of FDA-Approved Tests
While molecular assays remain the most accurate for detecting active infection, the performance of serological and some rapid tests can vary. The FDA’s EUA process allowed for the rapid introduction of many tests, but ongoing evaluation of their accuracy and reliability is necessary. The need for rapid, scalable, and affordable testing continues to drive innovation in diagnostic technologies Habli2021Vashist2020Filchakova2022+1 MORE.
Conclusion
The FDA’s emergency use authorization process enabled the rapid approval and deployment of a diverse array of COVID-19 diagnostic tests, including molecular, serological, and innovative at-home options. These regulatory adaptations not only improved access to timely testing during the pandemic but also paved the way for future advancements in infectious disease diagnostics and public health response Larkin2022Ching2020Ravi2020+7 MORE.
Sources and full results
Most relevant research papers on this topic